MedPath

Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center logo
🇺🇸United States
Ownership
Private
Established
1884-01-01
Employees
10K
Market Cap
-
Website
http://www.mskcc.org

Phase II Trial of Preoperative Combined Modality Therapy for Esophageal Carcinoma: Cisplatin-Irinotecan Followed by Radiation Therapy With Concurrent Cisplatin and Irinotecan.

Phase 2
Completed
Conditions
Esophageal Carcinoma
Interventions
Radiation: External Beam Radiation Therapy
First Posted Date
2008-01-10
Last Posted Date
2016-01-25
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
61
Registration Number
NCT00590031
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma

Phase 2
Completed
Conditions
CNS Cancer
Intracranial Hemangiopericytoma
Meningioma
Hemangioblastoma
Neurofibromatosis
Interventions
First Posted Date
2008-01-10
Last Posted Date
2016-01-25
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
50
Registration Number
NCT00589784
Locations
🇺🇸

University of Virginia Health Science Center, Charlottesville, Virginia, United States

🇺🇸

Dana Farber Cancer Institute, Boston, Massachusetts, United States

🇺🇸

Memorial Sloan-Kettering Cancer Center at Commack, Commack, New York, United States

and more 3 locations

Germline BRCA1 and BRCA2 Mutations in Jewish Women Affected by Breast Cancer

Completed
Conditions
Breast Cancer
Interventions
Other: Blood test
Other: Questionnaire
First Posted Date
2008-01-10
Last Posted Date
2021-12-28
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
383
Registration Number
NCT00590109
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Menstrual Cycle Maintenance and Quality of Life: A Prospective Study

Active, not recruiting
Conditions
Breast Cancer
Menstrual Cycle
Amenorrhea
Interventions
Other: Questionnaire
First Posted Date
2008-01-10
Last Posted Date
2025-05-13
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
810
Registration Number
NCT00589654
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

Phase 2
Completed
Conditions
Lung Cancer
Non-small Cell Lung Cancer
Bronchioloalveolar Cancer
Interventions
First Posted Date
2008-01-08
Last Posted Date
2016-01-22
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
65
Registration Number
NCT00588445
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Immediate Vaginal Reconstruction After Oncologic Resection: Surgical Outcomes, Patient Satisfaction and Sexual Function

Not Applicable
Completed
Conditions
Vaginal Cancer
Interventions
Behavioral: QOL
First Posted Date
2008-01-08
Last Posted Date
2016-08-10
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
27
Registration Number
NCT00588081
Locations
🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases

Phase 2
Completed
Conditions
Brain Metastasis
Bladder Cancer
Breast Cancer
Colon Cancer
Melanoma
Cervical Cancer
HEENT Cancer
Prostate Cancer
Sarcoma
Lung Cancer
Interventions
Radiation: Stereotactic Radiosurgery
First Posted Date
2008-01-08
Last Posted Date
2016-02-22
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
51
Registration Number
NCT00587964
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Dose Augmented Rituximab and ICE for Pts With Primary Refractory and Poor Risk Relapsed Aggressive B-Cell NHL

Phase 2
Completed
Conditions
Lymphoma
B-cell Non-Hodgkin's Lymphoma
Interventions
Drug: Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant
First Posted Date
2008-01-08
Last Posted Date
2015-12-04
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
20
Registration Number
NCT00588094
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer

Not Applicable
Recruiting
Conditions
Prostate Cancer
Interventions
Drug: [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone
First Posted Date
2008-01-08
Last Posted Date
2025-03-21
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
300
Registration Number
NCT00588185
Locations
🇺🇸

Memorial Sloan Kettering Bergen (Consent Only), Montvale, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, United States

🇺🇸

Memorial Sloan Kettering Basking Ridge (Consent Only), Basking Ridge, New Jersey, United States

and more 4 locations

Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer

Phase 1
Completed
Conditions
Breast Cancer
Interventions
Other: Placebo
First Posted Date
2008-01-08
Last Posted Date
2015-12-24
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
45
Registration Number
NCT00588003
Locations
🇺🇸

Memorial Sloan-Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath